Home > Publications Database > Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia. > print

001     164245
005     20240328115559.0
024 7 _ |a 10.1186/s40635-017-0144-3
|2 doi
024 7 _ |a pmid:28677045
|2 pmid
024 7 _ |a pmc:PMC5496922
|2 pmc
024 7 _ |a altmetric:21611175
|2 altmetric
037 _ _ |a DZNE-2022-00901
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Al-Chalabi, Ahmed
|b 0
245 _ _ |a Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia.
260 _ _ |a Heidelberg
|c 2017
|b Springer Open
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1711540066_24243
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Novel extracorporeal procedures are constantly being developed and evaluated for use in patients with sepsis. Preclinical evaluation of such procedures usually requires testing in large animal models. In the present work, the safety and efficacy of a recently developed ADVanced Organ Support (ADVOS) system in a newly developed large animal two-hit model of liver failure combined with endotoxemia were tested.After establishing the model in more than 50 animals, a randomized study was performed. An inflammatory cholestatic liver injury was initially provoked in pigs. Three days after surgery, endotoxin was gradually administered during 7½ h. Animals were randomized to receive standard medical treatment either with (ADVOS group, n = 5) or without ADVOS (control group, n = 5). The ADVOS treatment was started 2½ h after endotoxemia and continued for 7 h. Survival, cardiovascular, respiratory, renal, liver, coagulation, and cerebral parameters were analyzed.Three days after surgery, cholestatic injury resulted in hyperbilirubinemia [5.0 mg/dl (IQR 4.3-5.9 mg/dl)], hyperammonemia [292 μg/dl (IQR 291-296 μg/dl)], leukocytosis [20.2 103/μl (IQR 17.7-21.8 103/μl)], and hyperfibrinogenemia [713 mg/dl (IQR 654-803 mg/dl)]. After endotoxemia, the ADVOS procedure stabilized cardiovascular, respiratory, and renal parameters and eliminated surrogate markers as bilirubin [2.3 (IQR 2.3-3.0) vs. 5.5 (IQR 4.6-5.6) mg/dl, p = 0.001] and creatinine [1.4 (IQR 1.1-1.7) vs. 2.3 (IQR 2.1-3.1) mg/dl, p = 0.01]. Mortality: All animals in the ADVOS group survived, while all animals in the control group expired during the 10-h observation period (p = 0.002). No adverse events related to the procedure were observed.The ADVOS procedure showed a promising safety and efficacy profile and improved survival in a sepsis-like animal model with dysfunction of multiple organs. An amelioration of major organ functions (heart and lung) combined with removal of markers for kidney and liver function was observed.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Albumin dialysis
|2 Other
650 _ 7 |a Animal model
|2 Other
650 _ 7 |a Cholestasis
|2 Other
650 _ 7 |a Endotoxemia
|2 Other
650 _ 7 |a Extracorporeal organ support
|2 Other
650 _ 7 |a Liver failure
|2 Other
650 _ 7 |a Multiple organ failure
|2 Other
650 _ 7 |a Sepsis
|2 Other
650 _ 7 |a Survival
|2 Other
650 _ 7 |a Swine
|2 Other
700 1 _ |a Matevossian, Edouard
|b 1
700 1 _ |a von Thaden, Anne
|0 P:(DE-2719)9000925
|b 2
|u dzne
700 1 _ |a Schreiber, Catherine
|b 3
700 1 _ |a Radermacher, Peter
|b 4
700 1 _ |a Huber, Wolfgang
|b 5
700 1 _ |a Perez Ruiz de Garibay, Aritz
|b 6
700 1 _ |a Kreymann, Bernhard
|b 7
773 _ _ |a 10.1186/s40635-017-0144-3
|g Vol. 5, no. 1, p. 31
|0 PERI:(DE-600)2740385-3
|n 1
|p 31
|t Intensive Care Medicine Experimental
|v 5
|y 2017
|x 2197-425X
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/164245/files/DZNE-2022-00901.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/164245/files/DZNE-2022-00901.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:164245
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000925
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-12
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-14T16:19:50Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-14T16:19:50Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-12
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-12
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-08-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-12
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-08-21
920 1 _ |0 I:(DE-2719)1140012
|k Animal Facility (Mouse) München
|l Animal Facility (Mouse)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1140012
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21